Suchen
Hoth Therapeutics Inc
HOTHZur Watchlist hinzufügen
1.360USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
21.02MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Hoth Therapeutics Inc Unternehmen
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Hoth Therapeutics Inc Informationen
BörsenkürzelHOTH
Name des UnternehmensHoth Therapeutics Inc
IPO-datumFeb 15, 2019
CEOKnie (Robb)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 15
Addresse1177 Avenue Of The Americas
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10036
Telefon16467562997
Websitehttps://hoththerapeutics.com/
BörsenkürzelHOTH
IPO-datumFeb 15, 2019
CEOKnie (Robb)
Führungskräfte von Hoth Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Hoth Therapeutics Inc?
Die fünf größten Anteilseigner von Hoth Therapeutics Inc sind: Dr. Jeff Pavell
Wie viele Institutionen halten Anteile an Hoth Therapeutics Inc (HOTH)?
Mit Stand vom 2026Q1 halten 43 Institutionen Anteile an Hoth Therapeutics Inc, mit einem Gesamtmarktwert von etwa 1.30M, was 6.79% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -245182.00 gestiegen.